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Abstract
Objective
The 5-item Compliance Questionnaire for Rheumatology (CQR5) proved reliability and validity in respect of identification 
of patients likely to be high adherers (HAs) to anti-rheumatic treatment, or low adherers (LAs), i.e. taking<80% of their 
medications correctly. The objective of the study was to validate an Italian version of CQR5 (I-CQR5) in rheumatoid 
arthritis (RA) patients and to investigate factors associated with high adherence.
Methods
RA patients, undergoing treatment with ≥1 self-administered conventional synthetic disease-modifying anti-rheumatic 
drug (csDMARD) or biological DMARD (bDMARD), were enrolled. The cross-cultural adaptation and validation of 
I-CQR5 followed standardised guidelines. I-CQR5 was completed by patients on one occasion. Data were subjected to 
factor analysis and Partial Credit model Parametrisation (PCM) to assess construct validity of I-CQR5. Analysis of 
factors associated with high adherence included demographic, social, clinical and treatment information. 
Factors achieving a p<0.10 in univariate analysis were included in multivariable analysis.
Results 
Among 604 RA patients, 274 patients were included in the validation and 328 in the analysis of factors associated with 
adherence. Factor analysis and PCM confirmed the construct validity and consistency of I-CQR5. HAs were found to be 
109 (35.2%) of the patients. bDMARD treatment and employment were found to be independently associated with high 
adherence: OR 2.88 (1.36-6.1), p=0.006 and OR 2.36 (1.21-4.62), p=0.012, respectively. 
Conclusion
Only one-third of RA patients were HAs according to I-CQR5. bDMARDs and employment status increased by almost 
3-fold the likelihood of being highly adherent to the anti-rheumatic treatment. 
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Introduction
Optimisation of treatment strategies 
and introduction of highly effective 
treatments, namely biological disease-
modifying anti- rheumatic drugs (bD-
MARDs), improved rheumatoid arthri-
tis (RA) outcomes in the last 30 years. 
Conventional synthetic DMARDs 
(csDMARDs) are the first line treat-
ment in RA due to their safety profile 
and relatively low cost (1-3). Addi-
tion of a bDMARD is recommended 
in patients with inadequate response 
to csDMARDs (2, 3). Adherence to 
csDMARDs is poor, with a proportion 
of adherent patients of 10–60% (4, 5). 
Despite the rapid onset of action, the 
high efficacy and the favourable safety 
profile of bDMARDs, adherence to this 
class of treatments is also sub-optimal 
(6, 7). Non-adherence to anti-rheumatic 
treatment is responsible for disease pro-
gression, unnecessary treatment escala-
tion and increase in the number of as-
sessments and hospitalization (5, 8-10). 
which result in increased costs and de-
creased quality of life (11, 12). Better 
understanding of patients’ adherence is 
an unmet need in RA and recent recom-
mendations for disease management 
advocate the investigation of potential 
implications of poor treatment adher-
ence (1, 3, 13).
Measuring adherence is complex and 
no standardised technique is available. 
In large-scale clinical studies, self-
reported questionnaires are the most 
common methods of assessing medica-
tion adherence and explore causes of 
poor adherence. Of the self-reported 
measures that have been developed to 
monitor medication adherence, most 
have limited sensitivity and have not 
been specifically developed for rheu-
matic diseases. The Compliance-
Questionnaire-Rheumatology (CQR) 
is a 19-item questionnaire developed 
in 1999 in the Netherlands. It identifies 
non-adherent patients and is specific 
for rheumatic diseases (14). However, 
CQR is lengthy at 19 items for use in a 
clinical setting. Hughes et al. tested the 
factor structure of CQR to reduce the 
number of items to 5 and performed a 
reliability and validation assessment of 
the resulting questionnaire, the 5-item 
CQR (CQR5) (15). CQR5 increases the 
clinical utility by diminishing the pa-
tient burden.  Only a few reports on ad-
herence measured with CQR5 are avail-
able (16, 17) and no report on treatment 
adherence, assessed by the means of a 
validated questionnaire, is available in 
Italian patients. 
The purpose of this study was to vali-
date an Italian version of CQR5 (I-
CQR5) in RA patients. Furthermore, we 
investigated what factors are associated 
with high adherence in patients treated 
with csDMARDs and bDMARDs. 
Patients and methods 
The study was conducted in two phas-
es. The first phase comprised the cross-
cultural adaptation and validation of I-
CQR5. The second phase was a cross-
sectional analysis conducted to identify 
factors associated with high adherence, 
defined by I-CQR5. 
Patients 
Patients were recruited in the outpatient 
clinic of Padova University Hospital be-
tween September 1, 2017 and January 
15, 2018. The inclusion criteria were: 
(1) diagnosis of RA according to the 
American College of Rheumatology 
1987 classification criteria (18); (2) dis-
ease duration>1 year; (3) aged 18 years 
or above; (4) ongoing treatment with at 
least one self-administered csDMARD 
or bDMARD (either oral, subcutane-
ous or intramuscular administration) 
(5) duration of the current treatment ≥6 
months. Inability to complete the ques-
tionnaire (i.e. patients with cognitive 
impairment or lack of proficiency in the 
Italian language) was an exclusion cri-
terion. All participants provided written 
informed consent before inclusion in the 
study. An additional consent was asked 
to the patients to retrieve anonymised 
clinical data from the local database. 
The study was carried out in accordance 
with the ethical standards of the Decla-
ration of Helsinki (1983) and was ap-
proved by the Ethics Committee for the 
clinical trials of the province of Padova. 
CQR5 
CQR5 is a 5-item, self-administered 
questionnaire that derives from the 
CQR. The original CQR has 19 items, 
and identifies patients as low adher-
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ers (LAs), i.e. taking <80% of their 
medication correctly, and high adherers 
(HAs) (14, 15, 19). The statements of 
the CQR were identified through focus 
groups and clinician’s expert opinion of 
the likely barriers to medication taking. 
The four point Likert answering scale 
ranges from: “definitely don’t agree” 
(scored 1) to “definitely agree” (scored 
4), with lower scores indicating lower 
levels of adherence. The CQR was 
validated against electronic medication 
event monitoring (eMEMs) devices to 
assess adherence and was found to cor-
rectly identify 62% of LA (19). 
CQR5 was developed after factor anal-
ysis of the CQR (15). Like the original 
CQR, CQR5 identifies LAs and HAs. 
The number of items was reduced to 
5, whilst retaining robust explanation 
of non-adherence to anti-rheumatic 
treatment. Items included in CQR5 are 
reported in Table I. A structure matrix 
identified the optimal linear combina-
tion of the CQR5 questions to maximise 
the discriminant ability. Fisher’s clas-
sification function coefficients resulted 
into two equations that allow comput-
ing one binary result (LA or HA). A 
spreadsheet was provided to compute 
the result of CQR5 by entering the score 
of each answer (15). CQR5 showed to 
explain 50.3% of the variance in adher-
ence, it has good internal consistency 
and fit to the data and detects 69% of 
LAs among RA patients (15).
Cross-cultural adaptation and 
validation of I-CQR5 
CQR5 was translated from English into 
Italian using the cross-cultural adapta-
tion process described by Beaton et al. 
(20). The process comprised five stages.
• I. Forward translation
The translation from English into Ital-
ian was carried out by two independ-
ent translators whose mother tongue 
was Italian (RP, EZ). Each translator 
provided a written report of the transla-
tion (T1 and T2) highlighting difficult 
phrases or uncertainties along with the 
rationale for their word choices.
• II. Synthesis of the translations
A synthesis of the two translation was 
produced by the 2 translators together 
(RP, EZ) with an unbiased moderator 
(LF) who mediated the discussion of 
translation differences arising from T1 
and T2. One common translation (T12) 
was obtained together with a report 
documenting the process and how is-
sues were resolved.
• III. Back- translation
Back-translation of T12 was undertak-
en by 2 independent translators whose 
mother tongue was English and who 
were blinded to the original versions 
(CC, JK). They produced 2 English 
translations (BT1 and BT2) (Table I). 
• IV. Expert committee assessment
The expert committee included all the 
people involved in the previous stages of 
the adaptation, together with a method-
ologist (MF), 3 health professionals (2 
doctors, CB and DA and 1 nurse, MM), 
and a member of the original CQR5 de-
veloping group (JD). The expert com-
mittee reviewed all translated versions 
(T1, T2, T12, BT1, BT2) in order to 
reach an agreement on all items and pro-
duce a provisional version of I-CQR5. 
• V. Field-testing
The provisional version of the I-CQR5 
was administered to 30 RA patients. 
Patients completed the I-CQR5 un-
aided. Cognitive interviews followed 
the questionnaire completion. During 
the interviews, both the meaning of the 
items and responses were explored. A 
report of the field-testing was presented 
to the expert committee to discuss po-
tential issues and, if needed, modify the 
questionnaire accordingly. 
The final version of I-CQR5 was com-
pleted by a first sample of patients 
fulfilling the inclusion criteria. The 
questionnaires were anonymous but 
contained self-reported data (gender, 
age, social status, education level and 
disease duration). Validation of the 
construct of I-CQR5 was tested on the 
first sample of patients completing the 
questionnaire. 
Analysis of factors associated 
with high adherence
To analyse factors associated with high 
adherence, I-CQR5 was administered 
to the patients who provided consent 
to retrieve their clinical data. HAs 
and LAs were defined according to I-
CQR5. Patients’ information was col-
lected from the local database. A code 
allowed the association of the ques-
tionnaire result with patients’ informa-
tion by a blinded investigator. 
Data collected were: gender, age, so-
cial status (defined as: living with par-
ents and family/living /alone/living 
with partner and family/other), educa-
tion level, employment, smoking hab-
its, BMI, distance from the outpatient 
clinic, number of rheumatologic as-
sessments per year, positive rheumatoid 
factor (RF) and/or anti-citrullinated 
peptides antibodies (ACPA), disease 
duration, concomitant fibromyalgia, 
csDMARD and bDMARD treatment 
and dose, route and frequency of ad-
ministration, treatment duration (≤ or 
>24 months), combination treatment 
(≥2 synthetic and/or bDMARDs), pre-
vious bDMARD failures, mean cor-
ticosteroid daily dose, non-steroideal 
antinflammatory drugs (NSAIDs) use, 
painkillers use, concomitant chronic 
treatments, 28-joint disease activ-
ity score (DAS28), Health Assessment 
Questionnaire (HAQ), patients’ and 
physicians’ global health measured on 
a visual analogic scale (patient- and 
physician-VAS) and self-reported dis-
ease flares in the three months before 
the assessment (21). DAS28 was calcu-
lated using C-reactive protein; remis-
sion was defined as a DAS28<2.6, low 
disease activity as a DAS28≤3.2 (22). 
Demographic, clinical and treatment in-
formation was collected the day of the 
questionnaire completion. 
Corticosteroids were used at a dose of 
≤7.5 mg prednisone-equivalents. Con-
sidered csDMARDs were: methotrex-
ate (10–25 mg weekly), leflunomide 
(20 mg daily or every 2 days), or other 
csDMARDs (i.e. hydroxychloroquine 
200–400 mg/day or sulfasalazine 2–3 
g/day). Considered bDMARDs were: 
abatacept, adalimumab, anakinra, 
certolizumab pegol, etanercept, goli-
mumab and tocilizumab. Patients could 
receive either full-dose or low-dose 
bDMARD. In our clinical practice, 
patients who maintain remission for at 
least 6 months on a full-dose bDMARD 
undergo dose reduction (23). Low-dose 
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treatments were: abatacept 125 mg or 
tocilizumab 162 mg or etanercept 50 
mg every ≥10 days, adalimumab 40 mg 
or certolizumab pegol 200 mg every ≥3 
weeks, anakinra 100 mg every ≥2 days, 
etanercept 25 mg every ≥1 week, goli-
mumab 50 mg every ≥45 days. 
Statistical analysis 
• Data description 
Descriptive statistics of data accord-
ing to the result of I-CQR5 were per-
formed. Wilcoxon-Kruskal-Wallis test 
was performed for continuous vari-
ables and Pearson Chi-square test for 
categorical ones to discriminate among 
stratification variables.
• Questionnaire validation
A maximum-likelihood factor analysis 
was conducted in order to identify the 
number of latent dimensions underly-
Table I. Report of the Expert Committee Assessment: original 5-item Compliance Questionnaire for Rheumatology (English), back-
translations, issues discussed and final agreement. 
Original Back-translation 1 (BT1) Back-translation 2 (BT2) Issues Agreement
Title    
5 Item version of the Compliance  Questionnaire on 5-Item Questionnaire on Uncertainty on the use of the term “compliance” Questionario sulla
Questionnaire for Rheumatology  Rheumatology Compliance Compliance in Rheumatology was discussed. The Italian term “aderenza”  Compliance in
 composed of 5 questions.   seemed more appropriate to describe patients’  Reumatologia a 5 domande.
   agreement on the treatment they have been 
   prescribed. Nevertheless, “aderenza” could be 
   translated into the English term “adherence” 
   while “compliance” allows to specifically refer 
   to the original questionnaire version.  
Acronym    
CQR5 – – – I-CQR5
Introduction    
On the next pages you will find a  Below there are some Below there are statements Considering the mean age of patients with Di seguito sono riportate
number of statements made by statements made by patients made by patients with rheumatoid arthritis, it was deemed more delle affermazioni di 
patients with a rheumatic disease.  affected by rheumatic rheumatic diseases. Please, pragmatically suitable to adopt a more formal pazienti affetti da una
Please indicate for each statement  diseases. Indicate to what circle the number that best style. malattia reumatica. Indichi
how far you agree, by placing a extent you agree with each  reflects your opinion. The first singular person statements were turned quanto è d’accordo con
circle around the number that statement by circling the   into the formal pronoun accordingly. ciascuna affermazione
reflects your opinion best. number that best reflects  Different options for the translation of  cerchiando il numero che
 your opinion.   “to find”, “statements”, “how far” are available riflette maggiormente la 
   in the Italian language. The choice has been  Sua opinione.
   made in order to maintain a formal style.   
Item no. 1    
I take my anti-rheumatic medicines I take my antirheumatic  I take the antirheumatic Translation of “to take” was discussed. Prendo i farmaci
because I then have fewer problems medication so that I’ll have  medication so I can feel “Assumere” was a suitable term according to antireumatici perché in
 less symptoms. better. the formal style of the questionnaire, but it questo modo ho meno 
   usually refers to oral medications. “Prendere”  disturbi.
   is less formal but it was deemed appropriate as 
   it has a broader meaning referring also to 
   subcutaneous and intramuscular treatments. 
Item no. 2    
I definitely don’t dare to miss my  I don’t ever allow myself to I never skip my medication. None. Non mi permetto mai di
anti-rheumatic medications  skip taking my medication.    saltare la somministrazione  
    dei farmaci antireumatici. 
Item no. 3    
My medicines are always stored I always put my medication  I put my medication in the Translation of “to store” was discussed. Metto sempre le medicine
in the same place and that’s why in the same place so that same place so I don’t forget  “Mettere in un posto” was deemed an nello stesso posto per non
I don’t forget them  I don’t forget to take it. to take it.  adequate translation.  dimenticare di prenderle. 
Item no. 4    
I take my medicines because I take my prescribed  I take the medication my Translation of “to take” was discussed Prendo i farmaci prescritti
I have complete confidence in my  medication because rheumatologist prescribed (see item no.2). perché ho completa fiducia
rheumatologist I have complete faith in my  because I trust him/her  nel mio reumatologo.
 rheumatologist. completely.   
Item no. 5    
What the doctor tells me, I always follow my doctor’s I always follow my doctor’s  Uncertainty has arisen on the type of doctor the Seguo sempre le indicazioni
I hang on to  instructions. recommendations. item refers to, either the general practitioner  del mio medico.
   or the rheumatologist. The committee deemed 
   that the original distinction between the 
   rheumatologist (in Item no. 4) and the doctor 
   (Item no. 5) should be kept to ensure the same 
   consistency of the original questionnaire. 
   The term “medico” was chosen instead of 
   “dottore”, as “medico” specifically refers to 
   the medical doctor.  
Answers    
Don’t agree at all Don’t agree at all Don’t agree at all Translation was chosen according to the most Completam. in disaccordo
Don’t agree Don’t agree Don’t agree common Likert-scale answers adopted in the In disaccordo
Agree Agree Agree main Italian questionnaires, e.g. those used by D'accordo  
Agree very much Agree very much Agree very much the National Italian Institute of Statistics Completamente d’accordo
    (ISTAT).
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ing the observed variable distribution 
(24). Based on the Chi-square statis-
tics we tested the hypothesis that the 
model, based on the actual number of 
dimensions, was fitting the data with a 
minimal loss of information. The vari-
ables with the greater percentage of ex-
plained variance in the first two latent 
factors were included as subset item in 
the Martin-Loef test (25) to assess the 
assumption of unidimensionality in a 
Partial Credit model Parametrisation 
(PCM) (26). PCM was estimated to 
test whether I-CQR5 retained its psy-
chometric properties following the ad-
aptation process (26). The model was 
estimated including responses with at 
least one valid response per item and 
the item-fit statistics was reported in or-
der to assess deviations from the PCM 
assumption for each item of the scale. 
Internal Consistency was analysed, in-
cluding the Patient Separation Index 
(PSI) measure (27). PSI quantifies the 
error associated with the measurements 
of subject in this sample with values 
>70 indicating an adequate reliability.
• Multivariable analysis
A multivariable logistic regression 
analysis was performed to evaluate 
factors associated with high adherence 
to anti-rheumatic treatment. Variables 
included in the multivariable analysis 
were all those with a p<0.10. Collinear-
ity was assessed by the variance infla-
tion factor (VIF), adopting a cut off=2 
as an exclusion criterion (28). Analyses 
were performed using R 3.3.3 (29) with 
arms (30) and eRm (31) packages. 
Results 
Among 604 consecutive RA patients, 
401 fulfilled the enrolment criteria. 
Thirty patients were involved in the 
field testing, 274 in the cross-cultural 
validation and 328 in the cross-section-
al analysis (Supplementary Fig. 1). 
Cross-cultural adaptation and 
validation of I-CQR5 
The expert committee assessment 
discussed discrepancies raised in the 
stages of the translations and reached 
a consensus on all items. Report of 
the assessment is reported in Table I. 
During the field-testing, I-CQR5 was 
well understood by patients and no 
major issue arose. Thus, the commit-
tee deemed that the aim of proposing 
an accurate Italian version of the CQR5 
was achieved. The final I-CQR5 (Table 
I) was completed by 274 patients on 
one occasion. Characteristics of the 
patients and data of the questionnaires 
used in the validation phase are report-
ed in Supplementary Table I. 
• Factor analysis
Assessment of the response structure 
in the 5 items, revealed ordered thresh-
olds in most items. Factor analysis re-
vealed that two factors were sufficient 
to explain the overall variability: the 
cumulative percentage of explained 
variance was 0.82 (Table II) and it was 
possible to accept the hypothesis that 
the model fitted the data perfectly (Chi-
square=0.46, p=0.5). 
• Rasch model (Partial Credit model 
Parametrisation)
The assessment of the response struc-
ture revealed that, observing location 
parameters, thresholds were ordered in 
most items, implying that the 4-point 
category structure worked as expected 
(Table II). Item-fit statistics showed 
an overall agreement of items with 
proposed parametrisation as the Mean 
Square Error Item fit statistics were 
comprised between 0.6–1.4 (excluding 
item no. 5), according to Wright & Li-
nacre (1994) (Table II). The Chi-square 
test showed agreement with PCM by 
item (excluding item no.1) (Table II). 
Martin-Loef test, without covariates, 
confirmed the unidimensionality of 
scales (Chi-square 65.8, degrees of 
freedom (df) 53, p=0.11). The Separa-
tion Reliability Index proved the inter-
nal consistency of the scale (PSI 0.91). 
Martin-Loef test for the scale invariance 
for gender, age, education level and so-
cial status showed that the scale was 
invariant to age (Chi-square=40.56, 
df=28, p=0.059), education level (Chi-
square=49.95, df=42, p=0.187), so-
cial status (Chi-square=10.46, df=15, 
p=0.79) and disease duration (Chi-
square=13.63, df=36, p=0.220); while 
the test was significant for gender (Chi-
square=25.39, df=14, p=0.031). 
Factor analysis showed that I-CQR5 
fitted the data and proved its unidi-
mensionality and internal consistency. 
I-CQR5 could be then administered to 
a larger sample of patients for further 
analyses. The final version of I-CQR5 
is reported in Suppl. Figure 2. 
Analysis of factors associated 
with high adherence 
Characteristics of patients included in 
the cross-sectional analysis are detailed 
in Table III. The median duration of the 
current treatment was 7 years (3.3–10.1). 
Most of the patients were treated with 
bDMARDs and half with csDMARD 
treatment. Ninety per cent of the patients 
was in low disease activity or in remis-
sion: 270 (90.3%) and 173 (57.9%), 
respectively. HAs were 109 (35.2%) of 
all patients according to I-CQR5 (Table 
III). Variables significantly associated 
with high adherence to treatment were: 
younger age, employment, higher level 
Table II. Factor analysis: the proportions of contribution to latent factors provided by ques-
tionnaire items, the sum of square loadings, proportion and cumulative proportion of ex-
plained variance are reported for each item. Partial Credit model Parametrisation threshold 
analysis reports mean Square Item-fit statistics and location parameters.
 Factor analysis  Partial credit model parametrisation
 loadings  threshold analysis
 All† HAs         Outfit mean  Infit mean Location
    square square  Parameters
Item no. 1 0.721 0.460 Item no. 1 1.219 1.111 0.44
Item no. 2 0.629 0.522 Item no. 2 1.119 1.132 0.55
Item no. 3 0.750 0.522 Item no. 3 0.777 0.740 0.91
Item no. 4 0.660 0.675 Item no. 4 0.517 0.523 0.98
Item no. 5 0.534 0.807 Item no. 5 0.7171 0.682 0.83
 Factor 1 Factor 2    
Sum of square loadings 2.210 1.869    
Proportion variance 0.442 0.374    
Cumulative variance 0.442 0.816 
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of education (secondary school/univer-
sity), bDMARD treatment, lower medi-
an prednisone dose, lower patient-VAS, 
higher distance from the outpatient clin-
ic. The use of a csDMARD, particularly 
MTX and HCQ/SSZ, was significantly 
associated with low adherence to treat-
ment (Table III). 
Values achieving a p<0.10 in univari-
ate analysis, were included in the lo-
gistic regression model (Table IV). Age 
resulted collinear with employment 
(VIF=2.05 and 1.67, respectively). 
Thus, two separate regression analy-
ses were conducted, one including age 
and one including employment. The 
model including age was not significant 
(Suppl. Table II). The model including 
employment is reported in Table IV. 
Treatment with a bDMARD and em-
ployment resulted predictors of high 
adherence increasing by 2–3-fold the 
likelihood of being HAs (Table IV). 
Discussion 
This is the first study to evaluate ad-
herence in RA patients by means of 
I-CQR5, a validated Italian version 
of CQR5 questionnaire. I-CQR5 was 
well understood by patients and very 
little time-consuming for the physi-
cian. Only one third of RA patients was 
highly adherent to treatment according 
to I-CQR5. Treatment with bDMARDs 
and employment were associated with a 
2-3 times increased likelihood of being 
highly adherent to treatment. 
Poor adherence to treatment was more 
common in our cohort than in previous 
reports, although a comparison is dif-
ficult to perform because of the differ-
ent methods used to assess adherence. 
In surveys including bDMARDs, good 
adherence was reported to be around 
50–90% (6, 7, 32), nevetheless reports 
of adherence as low as 11% were de-
scribed (33). Studies using CQR5 are 
only a few and do not have comparable 
cohorts of RA patients (16, 17). Adher-
ence rates measured with the original 
19-item CQR show rates of HAs around 
65–90% (34-38). CQR has been re-
ported to identify approximately a dou-
bled rate of LAs compared with other 
questionnaires (39). Lower rates of high 
adherence may be entailed by the dis-
crete distinction of adherence in two 
Table III. Analysis of factors associated with high adherence defined by I-CQR5: demo-
graphics and clinical characteristics of the patients according to high and low adherence 
(n=310).
  Total HAs LAs p-value
No. 310  109  201  -
Females (%) 232 (82) 88 (85.4) 144 (80) 0.081||
Age, years, median (IQR) 57 (48-67) 54 (46-64.8) 59 (49-66) 0.011||
BMI, median (IQR) 24 (22-28) 25 (23-28) 24 (21-27.3) 0.094||
Smokers, n (%) 45 (17.2) 13 (16) 32 (17.7) 0.746
Employed, n (%) 127 (44.1) 58 (62.4) 69 (35.4) p<0.001||
Education level       0.114
Primary school, n (%) 35 (12.1) 10 (9.4) 25 (13.6) 
Middle school, n (%) 115 (39.7) 35 (33) 80 (43.5) 
Secondary school, n (%) 101 (34.8) 45 (42.5) 56 (30.4) 
University, n (%) 39 (13.4) 16 (15.1) 23 (12.5) 
Primary/middle school education, n (%)  150 (51.7) 45 (30) 105 (70) 0.016||
Social status       0.921
Living with parents and family 18 (7) 6 (7.5) 12 (6.8) 
Living alone 34 (13.2) 10 (12.5) 24 (13.6) 
Living with partner and family 187 (72.8) 57 (71.3) 130 (73.4) 
Other 18 (7) 7 (8.8) 11 (6.2) 
Positive RF and/or ACPA, n (%) 166 (56.3) 51 (49.0) 115 (60.2) 0.178
Disease duration, years, median (IQR) 12 (7-19) 12 (7.3-18) 11 (6.8-20) 0.876
Fibromyalgia, n (%) 51 (18) 15 (14.6) 36 (20) 0.252
csDMARD treatment, n (%) 165 (54.5) 44 (40.7) 121 (62.1) p<0.001||
Methotrexate, n (%) 114 (37.6) 32 (29.6) 82 (42.1) 0.033
Leflunomide, n (%) 31 (10.2) 8 (7.4) 23 (11.8) 0.227
Other csDMARD, n (%) 42 (13.9) 7 (6.5) 35 (17.9) 0.006
bDMARD treatment, n (%) 193 (64.3) 79 (76.7) 114 (57.9) 0.001||
Treatment duration>24 months, n (%) 178 (79.5) 75 (78.1) 103 (80.5) 0.667
Prednisone daily dose, median (IQR) 1 (0-5) 1 (0-2.5) 1.5 (0-5) 0.011||
NSAIDs, n (%) 185 (65.6) 62 (62.6) 123 (67.2) 0.439
Painkillers, n (%) 76 (28.6) 30 (30.6) 46 (27.4) 0.574
Concomitant chronic treatment, n (%) 156 (53.1) 51 (49) 105 (55.3) 0.307
DAS28, median (IQR) 2.3 (1.8-2.8) 2.1 (1.7-2.7) 2.3 (1.9-2.3) 0.088||
Remission*, n (%) 173 (57.9) 60 (55.6) 113 (59.2) 0.544
Low disease activity¥, n (%) 270 (90.3) 101 (93.5) 169 (88.5) 0.158
Patient - VAS, median (IQR) 30 (10-51) 20 (6-54) 40 (20-56.3) 0.003||
Physician - VAS, median (IQR) 10 (5-20) 12.5 (1.3-20) 10 (5-20) 0.984
HAQ, median (IQR) 0.5 (0-1) 0.3 (0-1) 0.5 (0.1-1) 0.114
Disease flares, median (IQR) 44 (31.4) 10 (27) 34 (33) 0.501
No. of assessments per year, median (IQR) 3 (2-4) 3 (2-4) 3 (2-4) 0.490
Distance from clinic, km, median (IQR) 30 (11-45) 30 (20-50) 25 (9-45) 0.037||
*Remission was defined as DAS28<2.6; ¥low disease activity was defined as DAS28<3.2; ||variables 
included in the multivariable analysis as achieving a p-value<0.10 in the univariate analysis. 
Has: high adherers; LAs: low adherers; IQR: interquartile range; BMI: body mass index; ACPA: 
anti-citrullinated peptides; RF: rheumatoid factor; csDMARD: conventional synthetic DMARD; 
bDMARD: biological DMARD; DMARD: disease-modifying anti-rheumatic drug; NSAIDs: non-
steroideal anti-nflammatory drugs; HAQ: Health Assessment Questionnaire; DAS28: disease activity 
score in 28 joints; VAS: visual analogue scale. 
Table IV. Factors associated with high adherence to anti-rheumatic treatment defined by 
I-CQR5: multivariable regression analysis model. 
 OR (95% CI) p-value
Female gender 0.79 (1.58-0.39) 0.501
Employment 2.36 (1.21-4.62) 0.012
bDMARD treatment 2.88 (1.36-6.1) 0.006
Patient-VAS (per 10-unit increase) 0.88 (0.78-1) 0.052
Model constant   <0.001
OR: odds ratio; CI: confidence interval; DMARD: disease-modifying anti-rheumatic drug; bDMARD: 
biological DMARD; VAS: visual analogue scale.
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categories (taking correctly ≥ or <80% 
of prescribed medications, i.e. HAs or 
LAs) given by CQR and CQR5. To ex-
plain the rather low rates of good adher-
ence, it has to be considered that CQR 
and CQR5 seem to explore the general 
attitude of the patient toward the anti-
rheumatic treatment and the health-care 
providers. Actually, only one question 
of CQR5 investigates the correct medi-
cation intake (item no. 2, on skipping 
medication). Other questionnaires, such 
as the Medication Adherence Scale and 
the Morisky adherence questionnaire, 
which have been also used in RA, have 
several items addressing specifically 
the administration of medications. Fur-
thermore, CQR proved to correlate well 
with patient-reported outcomes, but not 
with other questionnaires on adherence 
(41). Likewise, CQR5 results were asso-
ciated with the results of the Beliefs on 
Medications Questionnaire, (40) which 
identifies patients with concerns or mis-
beliefs regarding the medical treatment. 
One reason for the low rate of high ad-
herence observed in the study might be 
that almost 90% of the patients were 
in remission or low disease activity. In 
fact, self-discontinuation of anti-rheu-
matic treatment is described in patients 
with low levels of pain, as they might 
feel that treatment is unnecessary (41). 
In our study, the high rate of patients 
with low disease activity might be ex-
plained by the stable treatment and the 
large number of bDMARDs therapies. 
Although, we found no association with 
measures of RA activity, one can as-
sume that patients with very good con-
trol of disease activity decrease treat-
ment on purpose.  That being so, LAs 
may include both patients not needing 
to comply because of low disease activ-
ity and patients with active disease who 
are not taking the treatment properly. 
High adherence to treatment was less 
frequently observed in patients treated 
with csDMARDs compared with bD-
MARDs, which is consistent with pre-
vious findings (5, 7, 33, 42-46). Patients 
prefer bDMARDs as they usually have 
a faster and greater effectiveness, but 
also because they are innovative and 
costly (5, 33). This awareness might 
foster the feeling of a privileged health 
care with bDMARDs (33). No signifi-
cant association has been previously 
reported between employment and ad-
herence (11, 32, 47). In our cohort em-
ployed patients were younger and had a 
higher educational level, and both fac-
tors affected positively adherence. Nev-
ertheless, employment was indepen-
dently associated with high adherence. 
Concerns about reduced working abil-
ity considerably bother RA patients and 
full functionality is essential to ensure 
working productivity (48, 49), thereby 
encouraging a compliant behaviour in 
employed patients.
The study has some limits. Firstly, ques-
tionnaires are prone to biased results 
from socially desirable answering (50). 
The adoption of an anonymous ques-
tionnaire and the correct item construc-
tion and validation can overcome these 
issues. Secondly, the study was conduct-
ed in a monocentric cohort of patients, 
where a large number of patients were 
treated with bDMARDs. Our cohort 
might be not representative of the RA 
population in Italy. In any case, recent 
evidences show that a lower rate of Ital-
ian patients is treated with bDMARDs 
compared with the rest of Europe (51). 
Given trends in other countries, our cen-
tre possibly preempts a pace that other 
services will follow in due course. One 
further limitation may be that most of 
the patients in the cohort had a good 
disease control which might also have 
affected adherence. Nonetheless, the 
study suggested that also patients who 
respond well to the treatment might be 
inclined to reduced compliance. 
This is the largest study to date explor-
ing the clinical utility of this simple 
questionnaire. Like previous reports, 
this study reports a higher adherence 
to bDMARDs compared with csD-
MARDs, but a rather poor overall ad-
herence to anti-rheumatic drugs. Ad-
dressing treatment adherence is rec-
ommended by guidelines for RA (1, 3, 
13), and I-CQR5 may serve as an initial 
screening of patients’ behavior in order 
to implement interventions to ame-
liorate adherence. I-CQR5 addresses 
both the compliance to treatment pre-
scription and the attitude of the patient 
toward the anti-rheumatic treatment. 
Furthermore, the study highlighted that 
LAs may be not only patients who skip 
the medication because of concerns re-
garding the treatment but also patients 
who reduce the medication because of 
good disease control. The latter group 
of patients might increase in the future 
because of the broad use of effective 
treatments, such as targeted synthetic 
DMARDs, which require oral daily 
administration and may be more sub-
jected to incorrect administration. Ad-
ditional investigations are needed to 
explore different grounds for reduced 
compliance. Possibly, interventions to 
improve adherence will have to include 
patients’ information and education. 
Shared decision to tailor treatment ac-
cording to disease activity and patients’ 
preferences is necessary to maximise 
the chances of good adherence. 
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